Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody persistence 6 years after MenC priming and response to Hib-MenC booster in healthy children
ISRCTN72858898Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Aug 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 4, open-label, single-arm trial of Hib-MenC-TT in meningococcal disease and Haemophilus influenzae type b disease (Hib), sponsored by University of Oxford. Primary endpoint: Serum bactericidal antibody to meningococcal serogroup C six years after priming immunisation. Started Aug 2006; status: completed.
02
Drugs
Hib-MenC-TT
03
Conditions
meningococcal diseaseHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on ISRCTN72858898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72858898.